Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Deffered Revenue (2022 - 2024)

Century Therapeutics (IPSC) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $109.8 million as the latest value for Q3 2024.

  • On a quarterly basis, Non-Current Deffered Revenue fell 2.12% to $109.8 million in Q3 2024 year-over-year; TTM through Sep 2024 was $109.8 million, a 2.12% decrease, with the full-year FY2023 number at $111.4 million, changed 0.49% from a year prior.
  • Non-Current Deffered Revenue was $109.8 million for Q3 2024 at Century Therapeutics, roughly flat from $109.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $115.8 million in Q1 2022 to a low of $109.2 million in Q2 2023.
  • A 3-year average of $111.2 million and a median of $110.8 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 1.09% in 2023; the steepest drop was 5.17% in 2023.
  • Century Therapeutics' Non-Current Deffered Revenue stood at $110.8 million in 2022, then rose by 0.49% to $111.4 million in 2023, then dropped by 1.45% to $109.8 million in 2024.
  • Per Business Quant, the three most recent readings for IPSC's Non-Current Deffered Revenue are $109.8 million (Q3 2024), $109.8 million (Q2 2024), and $110.3 million (Q1 2024).